{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:50:06Z","timestamp":1771548606451,"version":"3.50.1"},"reference-count":63,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The development of new drugs and subsequent novel combinations for the treatment of newly diagnosed multiple myeloma (NDMM) has resulted in a plethora of treatment options that can make the choice of initial induction therapy a challenge. A greater understanding of both patient- and disease-specific factors can provide a personalized approach to help design a treatment course. Historically, the choice of an induction regimen has been tethered to an initial impression of transplant eligibility at the time of diagnosis. As more effective and better-tolerated induction regimens have emerged, there has been increasing overlap in the induction strategies used for all patients with NDMM, which increasingly provide the ultimate goal of deep and durable remissions. The current treatment options and strategies for the management of NDMM are evaluated using the best available data to provide a rationale for these decisions.<\/jats:p>","DOI":"10.1182\/hematology.2022000404","type":"journal-article","created":{"date-parts":[[2022,12,9]],"date-time":"2022-12-09T16:13:11Z","timestamp":1670602391000},"page":"539-550","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Newly diagnosed multiple myeloma: making sense of the menu"],"prefix":"10.1182","volume":"2022","author":[{"given":"Caitlin L.","family":"Costello","sequence":"first","affiliation":[{"name":"University of California San Diego, La Jolla, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2022,12,9]]},"reference":[{"issue":"12","key":"2022121313291687700_hem2022000404C1","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"1","key":"2022121313291687700_hem2022000404C2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","article-title":"Total therapy with tandem transplants for newly diagnosed multiple myeloma","volume":"93","author":"Barlogie","year":"1999","journal-title":"Blood"},{"issue":"20","key":"2022121313291687700_hem2022000404C3","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1182\/blood-2014-11-568907","article-title":"New criteria for response assessment: role of minimal residual disease in multiple myeloma","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"issue":"23","key":"2022121313291687700_hem2022000404C4","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv"},{"issue":"10068","key":"2022121313291687700_hem2022000404C5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"14","key":"2022121313291687700_hem2022000404C6","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2022121313291687700_hem2022000404C7","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2022121313291687700_hem2022000404C8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-136907","article-title":"Survival analysis of newly diagnosed transplant-eligible multiple myeloma patients in the randomized Forte trial [abstract]","volume":"136","author":"Gay","year":"2020","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313291687700_hem2022000404C9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2018-99-112093","article-title":"Carfilzomib-lenalidomide-dexamethasone (KRd) induction-autologous transplant (ASCT)-KRd consolidation vs KRD 12 cycles vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction-ASCT-KCd consolidation: analysis of the randomized FORTE Trial in newly diagnosed multiple myeloma (NDMM) [abstract]","volume":"132","author":"Gay","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2022121313291687700_hem2022000404C10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N Engl J Med"},{"issue":"10192","key":"2022121313291687700_hem2022000404C11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"issue":"8","key":"2022121313291687700_hem2022000404C12","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"issue":"suppl 16","key":"2022121313291687700_hem2022000404C13","doi-asserted-by":"crossref","first-page":"8011","DOI":"10.1200\/JCO.2022.40.16_suppl.8011","article-title":"Daratumumab + lenalidomide, bortezomib, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma: a post hoc analysis of sustained minimal residual disease negativity from GRIFFIN [abstract]","volume":"40","author":"Rodriguez","year":"2022","journal-title":"J Clin Oncol"},{"issue":"25","key":"2022121313291687700_hem2022000404C14","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"2022121313291687700_hem2022000404C15","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma: the MANHATTAN nonrandomized clinical trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol"},{"issue":"suppl 16","key":"2022121313291687700_hem2022000404C16","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2022.40.16_suppl.8002","article-title":"Daratumumab carfilzomib lenalidomide and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: results of the phase 2 study IFM 2018-04","volume":"40","author":"Touzeau","year":"2022","journal-title":"J Clin Oncol."},{"issue":"4","key":"2022121313291687700_hem2022000404C17","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/2643-3230.BCD-21-0205","article-title":"Perspectives on the risk-stratified treatment of multiple myeloma","volume":"3","author":"Davies","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"15, suppl","key":"2022121313291687700_hem2022000404C18","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2019.37.15_suppl.8002","article-title":"Efficacy of carfilzomib lenalidomide dexamethasone (Kid) with or without transplantation in newly diagnosed myeloma according to risk status: results from the FORTE trial [abstract]","volume":"37","author":"Gay","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15, suppl","key":"2022121313291687700_hem2022000404C19","doi-asserted-by":"crossref","first-page":"8002","DOI":"10.1200\/JCO.2021.39.15_suppl.8002","article-title":"Carfilzomib-based induction\/consolidation with or without autologous transplant (ASCT) followed by lenalidomide \u00ae or carfilzomib-lenalidomide (KR) maintenance: efficacy in high-risk patients","volume":"39","author":"Gay","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10","key":"2022121313291687700_hem2022000404C20","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"2022121313291687700_hem2022000404C21","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1038\/s41409-022-01697-4","article-title":"KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma","volume":"57","author":"Gaballa","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2022121313291687700_hem2022000404C22","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","article-title":"Evaluation of daratumumab for the treatment of multiple myeloma in patients with high-risk cytogenetic factors: a systematic review and meta-analysis","volume":"6","author":"Giri","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"2022121313291687700_hem2022000404C23","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): a multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol"},{"issue":"7","key":"2022121313291687700_hem2022000404C24","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1200\/JCO.18.00685","article-title":"Autologous transplantation, consolidation, and maintenance therapy in multiple myeloma: results of the BMT CTN 0702 Trial","volume":"37","author":"Stadtmauer","year":"2019","journal-title":"J Clin Oncol"},{"issue":"19","key":"2022121313291687700_hem2022000404C25","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1056\/NEJMoa1114138","article-title":"Lenalidomide maintenance after stem-cell transplantation for multiple myeloma","volume":"366","author":"Attal","year":"2012","journal-title":"N Engl J Med"},{"issue":"19","key":"2022121313291687700_hem2022000404C26","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med"},{"issue":"9","key":"2022121313291687700_hem2022000404C27","doi-asserted-by":"crossref","first-page":"e431","DOI":"10.1016\/S2352-3026(17)30140-0","article-title":"Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial","volume":"4","author":"Holstein","year":"2017","journal-title":"Lancet Haematol"},{"issue":"10","key":"2022121313291687700_hem2022000404C28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"2022121313291687700_hem2022000404C29","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"2022121313291687700_hem2022000404C30","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10112261","volume":"10","author":"Holstein","year":"2021","journal-title":"J Clin Med"},{"issue":"16","key":"2022121313291687700_hem2022000404C31","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol"},{"issue":"19","key":"2022121313291687700_hem2022000404C32","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1056\/NEJMoa022340","article-title":"High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma","volume":"348","author":"Child","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"2022121313291687700_hem2022000404C33","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood-2003-07-2344","article-title":"Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning","volume":"103","author":"Bethge","year":"2004","journal-title":"Blood"},{"issue":"5","key":"2022121313291687700_hem2022000404C34","doi-asserted-by":"crossref","first-page":"910","DOI":"10.3324\/haematol.2016.162693","article-title":"A concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients","volume":"102","author":"Engelhardt","year":"2017","journal-title":"Haematologica"},{"issue":"5","key":"2022121313291687700_hem2022000404C35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"issue":"8","key":"2022121313291687700_hem2022000404C36","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"22","key":"2022121313291687700_hem2022000404C37","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N Engl J Med"},{"issue":"11","key":"2022121313291687700_hem2022000404C38","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"9513","key":"2022121313291687700_hem2022000404C39","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","article-title":"Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial","volume":"367","author":"Palumbo","year":"2006","journal-title":"Lancet"},{"issue":"3","key":"2022121313291687700_hem2022000404C40","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","article-title":"Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma","volume":"131","author":"Facon","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"2022121313291687700_hem2022000404C41","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1182\/blood-2018-99-111796","article-title":"Efficacy and feasibility of dose\/schedule-adjusted RD-R vs continuous Rd in elderly and intermediate-fit newly diagnosed multiple myeloma (NDMM) patients: RV-MM-PI-0752 phase III randomized study","volume":"32","author":"Larocca","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2022121313291687700_hem2022000404C42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2011-06-357038","article-title":"The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis","volume":"119","author":"Morgan","year":"2012","journal-title":"Blood"},{"issue":"6","key":"2022121313291687700_hem2022000404C43","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1182\/blood-2009-05-222539","article-title":"A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma","volume":"115","author":"Lokhorst","year":"2010","journal-title":"Blood"},{"issue":"10","key":"2022121313291687700_hem2022000404C44","doi-asserted-by":"crossref","first-page":"e479","DOI":"10.1016\/S2352-3026(18)30149-2","article-title":"Thalidomide before and after autologous stem cell transplantation in recently diagnosed multiple myeloma (HOVON-50): long-term results from the phase 3, randomised controlled trial","volume":"5","author":"van de Donk","year":"2018","journal-title":"Lancet Haematol"},{"issue":"9","key":"2022121313291687700_hem2022000404C45","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1182\/blood-2012-09-451872","article-title":"A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial","volume":"121","author":"Stewart","year":"2013","journal-title":"Blood"},{"issue":"13","key":"2022121313291687700_hem2022000404C46","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2011-11-374249","article-title":"IMWG consensus on maintenance therapy in multiple myeloma","volume":"119","author":"Ludwig","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2022121313291687700_hem2022000404C47","doi-asserted-by":"crossref","first-page":"185301865","DOI":"10.1038\/s41375-020-0724-1","article-title":"Response-adapted lenalidomide maintenance in newly diagnosed, transplant-eligible multiple myeloma: results from the multicenter phase III GMMG-MM5 trial","volume":"34","author":"Goldschmidt","year":"2020","journal-title":"Leukemia"},{"issue":"2","key":"2022121313291687700_hem2022000404C48","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"issue":"24","key":"2022121313291687700_hem2022000404C49","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol"},{"issue":"9","key":"2022121313291687700_hem2022000404C50","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/leu.2017.35","article-title":"Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA\/GEM trial","volume":"31","author":"Rosi\u00f1ol","year":"2017","journal-title":"Leukemia"},{"issue":"10168","key":"2022121313291687700_hem2022000404C51","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"393","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"issue":"suppl 1","key":"2022121313291687700_hem2022000404C52","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/blood-2021-147323","article-title":"Elotuzumab in combination with lenalidomide, bortezomib, dexamethasone and autologous transplantation for newly-diagnosed multiple myeloma: results from the randomized phase III GMMG-HD6 trial","volume":"130","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2022121313291687700_hem2022000404C53","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S1470-2045(10)70187-X","article-title":"Bortezomib, melphalan, and prednisoneversus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial","volume":"11","author":"Mateos","year":"2010","journal-title":"Lancet Oncol"},{"issue":"7","key":"2022121313291687700_hem2022000404C54","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1200\/JCO.2013.52.0023","article-title":"Bortezomib-melphalan-prednisone- thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival","volume":"32","author":"Palumbo","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"2022121313291687700_hem2022000404C55","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2011-02-338665","article-title":"Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation","volume":"118","author":"Morgan","year":"2011","journal-title":"Blood"},{"issue":"10","key":"2022121313291687700_hem2022000404C56","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa1402551","article-title":"Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma","volume":"371","author":"Benboubker","year":"2014","journal-title":"N Engl J Med"},{"issue":"33","key":"2022121313291687700_hem2022000404C57","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1200\/JCO.2014.58.7618","article-title":"Community-based phase IIIB trial of three UPFRONT bortezomib-based myeloma regimens","volume":"33","author":"Niesvizky","year":"2015","journal-title":"J Clin Oncol"},{"issue":"9","key":"2022121313291687700_hem2022000404C58","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2015-11-679415","article-title":"Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma","volume":"127","author":"Zweegman","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2022121313291687700_hem2022000404C59","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41408-020-0311-8","article-title":"Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT)","volume":"10","author":"Durie","year":"2020","journal-title":"Blood Cancer J"},{"issue":"12","key":"2022121313291687700_hem2022000404C60","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.3324\/haematol.2019.240374","article-title":"Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation: results from the randomized phase II HOVON-126\/NMSG 21.13 trial","volume":"105","author":"Zweegman","year":"2020","journal-title":"Haematologica"},{"issue":"26","key":"2022121313291687700_hem2022000404C61","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood.2020008787","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma","volume":"137","author":"Facon","year":"2021","journal-title":"Blood"},{"issue":"9758","key":"2022121313291687700_hem2022000404C62","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","article-title":"Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"21","key":"2022121313291687700_hem2022000404C63","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1182\/blood-2016-01-693580","article-title":"VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial","volume":"127","author":"Moreau","year":"2016","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/539\/2022877\/539costello.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2022\/1\/539\/2022877\/539costello.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T13:32:59Z","timestamp":1670938379000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2022\/1\/539\/493541\/Newly-diagnosed-multiple-myeloma-making-sense-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,9]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,9]]},"published-print":{"date-parts":[[2022,12,9]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2022000404","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12,9]]},"published":{"date-parts":[[2022,12,9]]}}}